These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27114600)

  • 21. Evaluation of Drugs for Use in Infants and Children: Where Are We Now, and Where Must We Go?
    Brown RE
    Anesth Analg; 2019 Oct; 129(4):1170-1174. PubMed ID: 30882517
    [No Abstract]   [Full Text] [Related]  

  • 22. Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives.
    Seegenschmiedt MH
    Strahlenther Onkol; 1998 Nov; 174 Suppl 3():25-9. PubMed ID: 9830452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refined common terminology criteria for adverse events criteria - respective systemic melanoma therapy.
    Kohlmann J; Kirsten H; Simon JC; Ziemer M
    Melanoma Res; 2019 Aug; 29(4):444-445. PubMed ID: 31246725
    [No Abstract]   [Full Text] [Related]  

  • 24. EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system.
    Rubin P; Constine LS; Fajardo LF; Phillips TL; Wasserman TH
    Radiother Oncol; 1995 Apr; 35(1):9-10. PubMed ID: 7569016
    [No Abstract]   [Full Text] [Related]  

  • 25. Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?
    Franzese O; Torino F; Giannetti E; Cioccoloni G; Aquino A; Faraoni I; Fuggetta MP; De Vecchis L; Giuliani A; Kaina B; Bonmassar E
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does age increase the risk of adverse drug reactions?
    Bégaud B; Martin K; Fourrier A; Haramburu F
    Br J Clin Pharmacol; 2002 Nov; 54(5):550-2. PubMed ID: 12445039
    [No Abstract]   [Full Text] [Related]  

  • 27. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug reactions from birth to early childhood.
    Gupta A; Waldhauser LK
    Pediatr Clin North Am; 1997 Feb; 44(1):79-92. PubMed ID: 9057785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.
    Heinzerling L; Ascierto PA; Dummer R; Gogas H; Grob JJ; Lebbe C; Long GV; McArthur G; Moslehi JJ; Neilan TG; Ribas A; Robert C; Schadendorf D; Wolchok JD; Hauschild A
    Eur J Cancer; 2019 May; 112():29-31. PubMed ID: 30903870
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection.
    Tuccori M; Montagnani S; Capogrosso-Sansone A; Mantarro S; Antonioli L; Fornai M; Blandizzi C
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):61-75. PubMed ID: 25363790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Side effects of antineoplastic therapy on the nervous system in children].
    Bode U
    Klin Padiatr; 1982; 194(6):351-8. PubMed ID: 6759782
    [No Abstract]   [Full Text] [Related]  

  • 33. Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II.
    Thomas CR; Stelzer KJ; Douglas JG; Koh WJ; Wood LV; Panicker R
    J Natl Med Assoc; 1994 Nov; 86(11):839-52. PubMed ID: 7807572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Side effects evaluation of ionizing radiation].
    Pointreau Y; Kreps S; Hennequin C
    Cancer Radiother; 2010 Jul; 14(4-5):246-9. PubMed ID: 20615744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine consequences of treatment of malignant disease.
    Shalet SM
    Arch Dis Child; 1989 Nov; 64(11):1635-41. PubMed ID: 2690741
    [No Abstract]   [Full Text] [Related]  

  • 36. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.
    Trotti A; Byhardt R; Stetz J; Gwede C; Corn B; Fu K; Gunderson L; McCormick B; Morrisintegral M; Rich T; Shipley W; Curran W
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):13-47. PubMed ID: 10758303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Terminology for reporting adverse events updated.
    Baldwin J
    J Natl Cancer Inst; 2003 Aug; 95(15):1103-4. PubMed ID: 12902434
    [No Abstract]   [Full Text] [Related]  

  • 38. Current variations in childhood cancer supportive care in the Netherlands.
    Loeffen EA; Mulder RL; van de Wetering MD; Font-Gonzalez A; Abbink FC; Ball LM; Loeffen JL; Michiels EM; Segers H; Kremer LC; Tissing WJ
    Cancer; 2016 Feb; 122(4):642-50. PubMed ID: 26588808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
    Trotti A; Colevas AD; Setser A; Rusch V; Jaques D; Budach V; Langer C; Murphy B; Cumberlin R; Coleman CN; Rubin P
    Semin Radiat Oncol; 2003 Jul; 13(3):176-81. PubMed ID: 12903007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of drug-related problem (DRP) classification systems: a review of the literature.
    Basger BJ; Moles RJ; Chen TF
    Eur J Clin Pharmacol; 2014 Jul; 70(7):799-815. PubMed ID: 24789053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.